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Since the introduction of cyclosporine-steroid therapy in 1980 for liver trans-
plantation. 1 year clinical survival rates have approached 70% for most of the 
common indications for liver replacement and 5 year survival rates are better 
than 60%. Nevertheless. allograft rejection continues to be a significant cause of 
retransplantation or death. Clinical rejection occurs in 70% of liver allograft 
recipients on cyclosporine-steroid therapy. Many patients require treatment 
with polyclonal or monoclonal antibody preparations to control acute cellular 
rejection. An increased risk of opportunistic infection. especially from cytome-
galovirus, is associated with such therapy. 
Nephrotoxicity is a principal and dose limiting side effect of cyclosporine. 
Chronic renal damage and functional impairment has been shown to occur in 
many liver transplant patients. Hypertension (secondary to direct renal effects 
of cyclosporine) requiring antihypertensive therapy is required in over half of 
these patients. Reduction of cyclosporine dose and/or combination therapy 
including lower dose cyclosproine. steroids and other agents. usually azathio-
prine. have been resorted to in order to maintain adequate immunosuppression 
while reducing intolerable side effects of cyclosporine. 
FK 506. a macrolide antibiotic produced from Streptomyces tsukubaensis. is 
produced by the Fujisawa Pharmaceutical Company, Ltd of Japan and is a new 
immunosuppressive agent which is at least 100 times more potent than cyclos-
porine. 
Animal models 
FK 506 was shown to be immunosuppressive in vitro by Kino et al. (1) and in 
rats by Inamura et ai. (2) It has demonstrated a remarkable ability to prolong 
allograft survival in a number of experimental animal models including renal. 
liver. and heart allografts (2-11). In studies conducted in Pittsburgh by Todo 
and co-workers in rats. dogs, and subhuman primates. no evidence of prohibi-
tive toxicity was found. In contrast. studies by Thiru et ai. reported serious 
toxicity consisting of widespread arteritis in dogs and baboons (12). However. 
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studies by Todo et al. and Ochiai et al. (13) have shown such vascular lesions to 
be present in non-immunosuppressed dogs after whole organ transplantation or 
in dogs treated with other agents including cyclosporine. Arteritis has not been 
seen in baboons treated with FK 506 or in other toxicology studies (10,11). 
Mechanism of action 
FK 506 has shown synergism with cyclosporine in experimental systems. The 
mechanism of action of FK 506, like that of cyclosporine. is not completely 
understood, but both agents. which are chemically unrelated, show similarities 
in their effects on T cells. 
In studies of the in vitro effects of FK 506 on cloned T cell activations, 
Sawada et al. have shown that FK 506 inhibits the response of cloned T cells 
to concanavalin A and to murine spleen cells in a dose-dependent manner at 
40- to 200-fold lower concentrations than cyciosporine. Allo-cytolytic T cell 
lymphocyte induction from murine thymocytes was inhibited, but not the ability 
of sensitized T cells to lyse specific target cells. Interleukin-2 (IL2) driven 
proliferation of activated cloned T cells was not inhibited. However, FK 506 
inhibited IL2 secretion and IL2 receptor expression on cloned T cells after 
stimulation by specific antigen. Cyclosporine has been shown to affect T cell 
activation in a similar manner but at far higher dosages. 
Yoshimura et al. (15) have demonstrated FK 506 dose dependent inhibition 
of IL-2 and gamma-interferon secretion by peripheral human bone marrow 
cells (PBMC) stimulated with phytohemagiutinin (PHA). FK 506 failed to 
inhibit B cell stimulating factor 2 (BSF-2) production by PBMC. Both cloned B 
and T cells, once activated, were not significantly affected by FK 506. 
Lymphocytes from primary MLR cultured in the presence of FK 506 did not 
allow for expression of alloantigen activated suppressor cells when used in a 
dose sufficient to inhibit CIL generation (16) .. Furthermore, there is evidence 
that both cyclosporine and FK 506 inhibit transcription of the IL-2 gene and 
that FK 506, like cyclosporine, acts on an early event in T cell activation (17). 
Phase I clinical trials of FK 506 were begun at the University of Pittsburgh 
with the approval of the Institutional Review Board and the US FDA, in 1989. 
The initial experience was reported at a special symposium held in Barcelona, 
Spain, in October 1989 (see Transplant. Proc. vol. 22, no. 2, February 1990). 
The following discussion will summarize the experience reported at that 
meeting. 
Rescue therapy with FK 506 
Our experience with the first 40 patients in which FK 506 was used for rescue 
of patients with intractible rejection or cyclosporine intolerance has been 
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reported by Fung et ai. (18) These are among the first human patients to be 
given FK 506. All patients entered into the study were treated with cyclos-
porine and prednisone prior to conversion to FK 506. Although some patients 
were switched to FK 506 purely because of cyclosporine intolerance, most were 
converted for uncontrolled liver allograft rejection despite maximal therapy with 
CsA and prednisone and many of these patients also had complications related 
to cyclosporine including renal dysfunction or hypertension. One patient was 
withdrawn from FK 506 therapy after 3 days when it was recognized that the 
patient had recurrent acute hepatitis rather than acute severe graft rejection. 
The remaining 39 patients were therefore considered treatment failures of 
conventional immunosuppression. 
There were 19 females and 21 males, ranging in age from 5 to 74 years. 
Liver biopsies were performed in all but 3 patients prior to entry and confirmed 
the diagnosis of cell mediated rejection. In 6 patients, it was the clinical 
impression that the biopsy findings underestimated the severity of rejection and 
in these patients the decision to rescue with FK 506 was based on clinical 
biochemical parameters. One patient was entered into the trial because of 
severe steroid intolerance. 
Thirty-nine allografts were studied definitively for at least one month or 
more and all but 8 of these were successfully rescued as judged by histopatho-
logic criteria and liver biochemistry studies. In each case, significant improve-
ment was observed in protocol liver biopsies obtained 2 weeks after the start of 
treatment with FK 506. Of particular interest was the apparent reversibility 
under FK 506 of the vanishing bile duct syndrome in those patients with some 
ducts still remaining in the portal triads. This lesion is usually refractory to 
treatment with conventional immunosuppression. 
Abnormalities in liver function tests also showed significant improvement. 
An early decline in the cannulicular enzymes (alkaline phosphatase and gamma-
GTP) was again of special interest since this correlated with the striking 
histological improvement seen in patients with vanishing bile duct syndrome. 
Similar improvements in hepatocellular enzymes (AST and AL T) were also 
observed in patients with histological improvement seen on protocol biopsies. 
One patient subsequently required retransplantation after successful reversal 
of rejection of his fifth liver graft by FK 506 because of hepatic artery 
thrombosis resulting from a technical flaw (a local anastomotic stricture). 
Pathological examination of the resected allograft showed no evidence of 
residual cell mediated rejection. The patient was given a sixth graft and has 
since been successfully sustained with this graft under continued immunosu-
pression with FK 506. 
Renal function 
Preexisting renal dysfunction was noted in approximately 70% of the patients 
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entered in this trial. Two patients had prior renal transplants and, in biopsies of 
both patients, cellular rejection and chronic fibrosis were seen, suggesting that 
both acute and chronic rejection of the kidney allograft was occurring. Cyclos-
porine nephrotoxicity was present in most of the other patients treated. 
The heterogeneity of the kidneys in patients in this study made it difficult to 
assess the nephrotoxicity of FK 506. Nine patients had such severe renal 
dysfunction at the time of switchover to FK 506, including hyperkalemia, that 
effective cyclosporine therapy was not possible. 
Evidence was observed that the effect of FK 506 on renal function is related 
to an interaction with cyclosporine and that FK 506 augmented cyclosporine 
nephrotoxicity. With the eventual elimination of cyclosporine after discon-
tinuance of this agent, a reduction in the BUN and Cr was eventually observed 
in most cases, in spite of therapeutic levels of FK 506. Two of the five patients 
who required hemodialysis recovered renal function. One patient required 
institution of hemodialysis, after bilateral renal vein thrombosis was discovered, 
shortly after institution of FK 506 therapy. Three patients required cadaveric 
renal transplantation for persistent renal failure during the course of FK 506 
therapy. 
Primary therapy with FK 506 
A phase 1 primary treatment study was begun in the latter half of 1989 and the 
initial 20 patients were reported by Todo (19). The following is a summary of 
33 adult conventional liver transplant recipients who had entered the protocol 
as of October 15, 1989. In addition, follow-up 3 patients, whose graft rejection 
could not reversed with the FK 506 'rescue' protocol and who therefore 
required retransplantation under FK 506, are also included. These are the first 
human patients to be given FK 506, along with low dose steroids, as their 
primary immunosuppressive baseline regimen. The results show the remarkably 
potent immunosuppressive qualities of FK 506 and its relative lack of toxicity in 
the first several months after transplantation. 
A biostatistical survival analysis (Kaplan-Meier) has been perfonned on the 
entire series of 33 patients with at lease one month of follow-up and a computer 
selected group of 81 CsA treated controls matched for age, sex, diagnosis, and 
clinical urgency (UNOS score). The FK 506 and CsA control patients were well 
matched for age, sex, and liver disease. but there was a higher proportion of 
critically ill patients (UNOS score 4) in the FK 506 treated patients than in the 
CsA treated controls. 
A subgroup of the first 20 these 33 patients, for whom follow-up for at least 
60 days is available. and a matched group of 20 CsA treated patients were 
compared for several outcome variables including measures of liver and renal 
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function. gastrointestinal tOXICity, hypertension. the incidence and severity of 
rejection, and the incidence and severity of major infections. 
FK 506, along with low dose steroid therapy, was used for all FK treated 
patients receiving primary liver allografts. as well as in the three surviving 
patients initially entered in the 'rescue' protocol and retransplanted under FK 
506. FK 506 therapy was initiated following liver transplantation. using a 
traditional steroid taper over 5 days. (In subsequent phases of the trial the initial 
high dose steroid taper has been eliminated and the patients simply started on 
prednisolone at 20 mg per day.) Doses of FK 506 were standardized to 0.15 
mg/kg/day as initial intravenous therapy, with conversion to oral FK 506 at 
ranges of 0.075 mg/kg/day to 0.30 mg/kg/day, based upon blood trough levels 
and observed side effects. A median of 6 days of intravenous FK 506 was 
given. before conversion to oral therapy. 
Patient survival: Only 2 patients in the initial primary series died. One 
patient. with primary pulmonary hypertension and unsuspected advanced 
atherosclerotic heart disease. prior to transplantation, died on postoperative day 
15. from heart failure with good liver function and histology. Another patient, 
who was critically ill (UNOS score 4) at the time of transplantation, developed 
thrombocytopenia after transplantation and died at 5 days of a hemorrhagic 
stroke. a well-known complication after liver transplantation, especially in 
critically ill patients. 
Figure 1 presents Kaplan-Meier plots comparing survival of the 33 patients 
receiving their first liver graft under FK 506 compared to patient survival for 
the 81 CsA treated and matched historical controls. Thirty-day patient survival 
for the FK treated patients is 93.9% compared to 87.6% for the CsA treated 
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Fig. 1. Patient survival (Kaplan-Meier plot) for primary liver transplantation under FK 506 
compared to cyciosponne-sterOld treated matched histoncal comrols. 
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effect on early patient survival. Moreover. although the plots were not yet 
different at a level of statistical significance. the trend suggested 50% improve-
ment for patients treated with FK 506 compared to those treated with esA. 
These early observations have been confirmed and achieved statistical signifi-
cance in our extended experience recently reported by Todo el al. (20). 
Liver allograft function 
Of the 36 liver allografts analyzed in the protocol (including the 3 retransplan-
tations), all functioned immediately, and no patient required retransplantation 
for primary graft non-function. 
Figure 2 presents Kaplan-Meier plots comparing primary graft survival of the 
FK 506 treated patients to primary graft survival for 81 grafts in the esA 
treated controls. In the FK 506 group, 30 of the 33 grafts are surviving 28 to 
80 days after transplantation. Actuarial survival at 30 days is 93.9% For the 
esA treated, matched controls, 30 day actuarial survival is 80.0%. The differ-
ences in survival had not yet reached statistical significance but the trend 
suggests a 65% improvement in early graft survival in the FK 506 treated 
patients. Again, subsequent longer follow-up and a larger case experience 
recently reported by Todo have confirmed the significance of these observa-
tions (20). 
Graft function after transplantation was also assessed by serial biochemical 
measurements. Bilirubin fell to normal levels much more rapidly in FK 506 
treated patients than in esA treated controls (Figure 3). The pattern of hepato-
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Fig. 2. Graft survival (Kaplan-Meier plot) for primary liver transplantation under FK 506 
compared 10 cyclosporine-slerold treated matched historical controls. 
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Fig. 4. Postoperative SGOT (ASl) for primary recipients of liver grafts treated with FK 506 
compared to CsA treated controls (from reference (19». 
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initial canalicular enzyme levels were higher in FK 506 treated patients, within 
2 weeks after transplantation, these levels fell and remained below those in the 
CsA treated controls (Figure 5). 
Rejection was seen in 60% of CsA treated patients compared to only 10% of 
the FK 506 treated patients. Additional immunosuppression was required in 18 
patients receiving CsA (17 received one or more courses of steroids, while 18 
received additional azathioprine, and 11 patients required OKT3). 
Two patients experienced significant rejection episodes occurring on post-
operative days 12 and 14, respectively. One was successfully controlled with 
augmented steroids and a 5 day course of OKT3. The other did not respond to 
steroids or azathioprine, and required retransplantation with a short course of 
OKT3. 
The low frequency and intensity of rejection episodes were demonstrable in 
protocol liver biopsies. In each case, the absence of lymphocytic cellular 
infiltrates and preservation of normal portal triad architecture were routinely 
observed in the first postoperative biopsy performed on the twelfth day after 
transplantation. In the two patients with clinical rejection, typical findings of 
cellular rejection were present. 
Steroid requirements 
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Fig. 5. Postoperanve canalicular enzymes (gOTP) for primary recipients of liver grafts treated 
with FK 506 compared to CsA treated controls (from reference ( 19)). 
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a that for patients treated with esA. The mean daily steroid dose in the FK 506 
.'T. patients was 9 mg/day at one month compared to 19 mg/day for the esA 
control group. 
Renal function 
FK 506 is not a classic nephrotoxin such as the aminoglycosides and does not 
produce renal cell death and acute renal failure. FK 506 does affect renal 
function but there are differences from the effects seen with esA. Elevations in 
postoperative renal function are not uniform. and promptly decline during the 
first week following transplantation. We have found a poor correlation (r -
0.45) between FK 506 drug level and serum creatinine (Ser) compared to the 
strong correlation (r - 0.88) seen between esA levels and Ser (r - 0.88). 
Thus. changes in changes in Ser, a dependable indicator of esA toxicity, is not 
such a reliable indicator of FK 506 toxicity. 
Among the 33 patients treated with FK 506 for their first graft, only one 
patient. who was on hemodialysis prior to transplantation. required dialysis 
after transplantation. This pateint. who eventually recovered, was in hepatorenal 
failure and was on dialysis prior to transplantation. This patient eventually 
recovered renal function and serum creatinine returned to normal levels while 
the patient was continued on FK 506. Three patients in the esA historical 
control group required hemodialysis during their initial hospital stay. 
FK 506 and esA treated patients were not matched for renal function and 
serum creatinine (Ser) was higher in the esA treated controls compared to FK 
506 treated patients at all time points, including prior to transplantation. 
Seventeen FK 506 treated patients and 12 esA control patients had a Ser less 
than 1.5 mg/dl prior to transplantation. In this subgroup, pretransplant Ser was 
less in the esA treated patients (0.62 ± 0.24 mg/dl) than in the FK 506 treated 
patients (0.74 ± 0.04 mg/dl). However. Ser was greater in the SsA treated 
subgroup thereafter. 
The acute rises in serum creatinine seen in the first patients treated for graft 
rescue with FK 506 were alarming. However. this is now believed to be a result 
of the combined severe nephrotoxicity of esA combined with the milder 
nephrotoxicity of FK 506. Prior exposure to esA and its resulting nephro-
toxicity leads to a predictable deterioration in renal function. but fortunately 
this improves after several weeks. FK 506 appears to have much less of a 
nephrotoxic effect in patients not previously treated with esA. Thus. patients 
being converted from esA to FK 506 are at higher risk of renal dysfunction 
than patients being treated primarily with FK 506. In patients not suffering from 
chronic esA nephrotoxicity, renal function is well preserved. 
Hyperkalemia was frequently seen both in esA and FK 506 treated patients. 
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Previous studies in CsA treated patients have usually found hyporeninemic 
hypo aldosteronism and this is also seen in patients treated with FK 506. In 
addition, there is an association between an increase in SCr and hyperkalemia, 
suggesting that a reduction in GFR also contributes to the retention of 
potassium. The hyperkalemia observed was moderate and responded in all 
cases to fludrocortisone acetate. 
Hypenension 
Hypertension is the second most troublesome side effect of treatment with CsA. 
No patient in the primary FK 506 group required addition of antihypertensive 
medication during the postoperative observation period. One patient with renal 
artery stenosis had some antihypertensive medications continued. although at a 
lower level than prior to transplantation. 
Gastrointestinal/metabolic effects 
The serum cholesterol level was statistically lower in the FK 506 treated group. 
as compared to the CsA group. Uric acid levels remained in the normal range 
in patients receiving FK 506. No differences in fasting blood sugar or pan-
creatic amylase were seen in FK 506 patients compared to CsA treated patients 
and no significant changes in the appearance of the pancreas have been seen on 
postoperative CT scans. 
Adverse reactions 
Unlike the patient population described for CsA to FK 506 conversion, this 
population of patients receiving FK 506 as primary therapy, had a much lower 
incidence of side effects. Side effects were assessed by careful interview of the 
patients by a trained nurse clinician. Although it can be difficult to determine 
whether subjective patient complaints are attributable to surgery itself or a side 
effect of medication. there were distinct differences in the incidence of side 
effects reported by patients taking oral FK 506 when compared to those 
reported by patients receiving intravenous drug. Eighty-seven percent of 
patients reported no significant side effects while taking oral FK 506 compared 
to 42% of patients on intravenous treatment. 
The most common side effect of primary intravenous FK 506 administration 
was headache. The headaches were usually described as mild and required 
narcotic analgesia in only 2 patients. The headaches responded to symptomatic 
<. 
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treatment and did not require reduction in dosages. Switching to oral adminis-
tration relieved the headache in all but 1 patient. 
The next most frequent side effects of intravenous therapy were gastroenter-
oiogic, especially nausea. Treatment consisted of antiemetics. and spontaneous 
resolution of these symptons occurred in all patients following conversion to 
oral therapy. With intravenous therapy, mild anorexia was sometimes associated 
with nausea. Oral intake was adequate in all patients. 
No adverse hemodynamic reactions, such as hypotension or other alterations 
in cardiac performance. were noted during the oral or intravenous administra-
tion of FK 506. Detailed cardiovascular profiles were developed during the 
initial intravenous infusion with FK 506. No patient required augmented anti-
hypertensive medications as an outpatient. 
Other side effects seen with intravenous FK 506 were a feeling of warmth 
and flushing. Less frequent side effects were rash, chest pain (without EKG 
changes). anxiety, abdominal cramping, night sweats, fatigue. photophobia, and 
blurred vision. These symptom complexes were also markedly reduced follow-
ing conversion from intravenous to oral FK 506. 
Infection 
The incidence of serious infections (defined as life-threatening infections), was 
not increased with the use of FK 506 when compared to CsA. In fact. the 
incidence of bacterial infections was low. occurring in only 4 patients in each 
group. Transient bacteremia from an indwelling intravenous catheter was seen 
in 1 patient on FK 506 and resolved with removal of the catheter. Two wound 
infections were seen, one mild and the other extending into subfascial planes 
which required drainage. One patient. treated for staphylococcal endocarditis 
prior to transplantation. developed spontaneous staphylococcal peritonitis while 
on FK 506. Viral infections. in particular cytomegalovirus (CMY) infections. 
were seen in 2 patients in the initial 20 FK 506 treated primary patients. as 
compared to 5 patients on CsA. These CMV infections were clinically mild and 
responded to treatment with gancyclovir. 
Charges and hospital stay 
An additional measure of the relative effectiveness and safety of FK 506 has 
been its impact on the length of hospital stay and related hospital charges after 
liver transplantation when compared to similar measures for CsA treated 
patients. The findings are even more striking when it is remembered that there 
was a significantly higher proportion of critically ill (UNOS class 3 and 4) 
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patients in the FK 506 treated group than in the CsA treated control group. 
Patients treated with CsA tended to stay in the hospital twice as long and 
accrued total bed charges almost three times greater than FK 506 patients (21). 
Pharmacologic monitoring 
Because of the possibility that FK 506 and cyclosporine would be used 
together. pharmacokinetic studies were performed with each drug individually. 
and then in combination, with both the intravenous and oral administration 
(22). Pharmacolinetic data of FK 506 suggests that the metabolism is primarily 
hepatic in nature. Peak levels in the 5-10 ng/ml range could be detected 1-2 
hours after intravenous administration. The terminal blood half-life appears to 
be 12 hours after a redistribution phase following an intravenous dose. The 
nature of absorption, peak levels and possibily the terminal half-life seem 
somewhat different following an oral dose. A relatively flat peak is generally 
seen, and the absorption of the oral dose is estimated at 30%. 
Both polyclonal and monoclonal immunoassay techniques have been per-
fected to monitor both blood and tissue levels of this drug and its metabolites. 
Conclusion 
FK 506 is an extraordinary immunosuppressive agent that has shown great 
promise in the early clinical trials in liver transplantation. It is much more 
potent than cyclosporine and, although it has a similar spectrum of side effects. 
it nevertheless appears to be much better tolerated than CsA. In particular, 
nephrotoxicity appears to be much milder with FK 506. Equally impressive is 
the ability of FK 506 to arrest the vanishing bile duct syndrome of chronic liver 
rejection at a later stage than with any previously available agent. Finally, the 
drug is much more effective than CsA in preventing acute rejection early after 
transplantation which permits early reduction in steroid dosage. avoids the need 
for use of antibody therapy and the penalties associated with the use such 
agents, and permits earlier discharge from the hospital after transplantation. 
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